NEW YORK (GenomeWeb News) – Entelos and the Institute for Systems Biology today announced a partnership that led to the integration of gene expression data into quantitative physiological simulations.
The new capability, they added, "improves understanding of the gene expression and disease outcome to radically improve the predictive discernment of the complex nature of disease." As a result, new insights into therapeutic targets, biomarkers, and patient selection can be gained.
Entelos and ISB collaborated to define a methodology that addresses "business-critical" problems in drug-development research and in healthcare, they said.
"This workflow is transformative for understanding the role of molecular interactions and their impact on pharmaceutical R&D and healthcare decision making," Entelos Founder and CTO Tom Paterson said in a statement. "By utilizing our computer models, we are able to use all identified correlations across gene network studies to decipher genetic influence on the disruptions identified as disease. As an example, the new capabilities were able to help us clearly define from a pool of 51 potential biomarkers, and which biomarkers identified non-responders and responders for anti-IL1 therapies for rheumatoid arthritis."
Entelos and ISB are currently seeking commercial partners "to advance existing disease models," including type 2 diabetes, atherosclerosis, hypertension, rheumatoid arthritis, and others, and generate new in silico applications.
Financial and other terms of the deal were not disclosed.